259 related articles for article (PubMed ID: 31646853)
1. Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease.
Pugliese D; Privitera G; Pizzolante F; Gasbarrini A; Guidi L; Armuzzi A
Minerva Gastroenterol Dietol; 2019 Dec; 65(4):280-290. PubMed ID: 31646853
[TBL] [Abstract][Full Text] [Related]
2. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease.
Restellini S; Khanna R; Afif W
Inflamm Bowel Dis; 2018 Sep; 24(10):2165-2172. PubMed ID: 29788272
[TBL] [Abstract][Full Text] [Related]
4. Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?
Alsoud D; Vermeire S; Verstockt B
Curr Opin Pharmacol; 2020 Dec; 55():17-30. PubMed ID: 33039940
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
Carman N; Mack DR; Benchimol EI
Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
[TBL] [Abstract][Full Text] [Related]
6. Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases.
Singh S; Dulai PS; Vande Casteele N; Battat R; Fumery M; Boland BS; Sandborn WJ
Aliment Pharmacol Ther; 2019 Oct; 50(8):848-857. PubMed ID: 31483522
[TBL] [Abstract][Full Text] [Related]
7. Proactive therapeutic drug monitoring and vedolizumab dose optimization in children with inflammatory bowel disease.
Rowland P; McNicol M; Kiel A; Maltz RM; Donegan A; Dotson JL; Michel HK; Boyle B
J Pediatr Gastroenterol Nutr; 2024 Apr; 78(4):853-861. PubMed ID: 38270212
[TBL] [Abstract][Full Text] [Related]
8. Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study.
Paul S; Williet N; Di Bernado T; Berger AE; Boschetti G; Filippi J; Del Tedesco E; Nancey S; Flourie B; Roblin X
J Crohns Colitis; 2018 Aug; 12(9):1089-1096. PubMed ID: 29860366
[TBL] [Abstract][Full Text] [Related]
9. Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease.
Guidi L; Pugliese D; Panici Tonucci T; Bertani L; Costa F; Privitera G; Tolusso B; Di Mario C; Albano E; Tapete G; Gremese E; Papa A; Gasbarrini A; Rapaccini GL; Armuzzi A
United European Gastroenterol J; 2019 Nov; 7(9):1189-1197. PubMed ID: 31700632
[TBL] [Abstract][Full Text] [Related]
10. Optimization of biologics to reduce treatment failure in inflammatory bowel diseases.
Bourchany A; Gilletta De Saint-Joseph C; Breton A; Barreau F; Mas E
Curr Opin Pharmacol; 2020 Oct; 54():51-58. PubMed ID: 32947075
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients.
Van den Berghe N; Verstockt B; Tops S; Ferrante M; Vermeire S; Gils A
J Gastroenterol Hepatol; 2019 Jul; 34(7):1175-1181. PubMed ID: 30589948
[TBL] [Abstract][Full Text] [Related]
12. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
[TBL] [Abstract][Full Text] [Related]
13. Postoperative outcomes in vedolizumab-treated pediatric patients undergoing abdominal operations for inflammatory bowel disease.
Lightner AL; Tse CS; Potter DD; Moir C
J Pediatr Surg; 2018 Sep; 53(9):1706-1709. PubMed ID: 29111083
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease.
Dutt K; Vasudevan A
Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399538
[No Abstract] [Full Text] [Related]
15. Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases.
Stevens BW; Borren NZ; Velonias G; Conway G; Cleland T; Andrews E; Khalili H; Garber JG; Xavier RJ; Yajnik V; Ananthakrishnan AN
Dig Dis Sci; 2017 Jan; 62(1):197-206. PubMed ID: 27796768
[TBL] [Abstract][Full Text] [Related]
16. Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview.
Pouillon L; Vermeire S; Bossuyt P
BMC Med; 2019 May; 17(1):89. PubMed ID: 31064370
[TBL] [Abstract][Full Text] [Related]
17. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
Mitrev N; Vande Casteele N; Seow CH; Andrews JM; Connor SJ; Moore GT; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; van Langenberg D; Ward MG; Leong RW;
Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1037-1053. PubMed ID: 29027257
[TBL] [Abstract][Full Text] [Related]
18. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
[TBL] [Abstract][Full Text] [Related]
19. A product review of vedolizumab in inflammatory bowel disease.
Battat R; Dulai PS; Jairath V; Vande Casteele N
Hum Vaccin Immunother; 2019; 15(10):2482-2490. PubMed ID: 30897022
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.
Papamichael K; Vande Casteele N; Ferrante M; Gils A; Cheifetz AS
Inflamm Bowel Dis; 2017 Sep; 23(9):1510-1515. PubMed ID: 28816757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]